Machina Capital S.A.S. Sells 14,870 Shares of Bristol Myers Squibb Company $BMY

Machina Capital S.A.S. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 51.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 13,993 shares of the biopharmaceutical company’s stock after selling 14,870 shares during the period. Machina Capital S.A.S.’s holdings in Bristol Myers Squibb were worth $873,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Davis Asset Management L.P. purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $27,000. Addison Advisors LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $32,000. Groupe la Francaise increased its holdings in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 501 shares during the period. Arlington Trust Co LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $35,000. Finally, Kilter Group LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julia Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $63.39 on Monday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The firm has a market capitalization of $129.57 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 0.33 and a beta of 0.20. The stock’s 50-day simple moving average is $61.90 and its 200-day simple moving average is $60.31.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.63 earnings per share. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.46 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Morgan Stanley lowered their price objective on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Bank of America reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Friday, October 30th. Cantor Fitzgerald reduced their target price on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research report on Wednesday, August 5th. Finally, Piper Sandler reduced their price objective on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $65.46.

View Our Latest Research Report on BMY

Key Stories Impacting Bristol Myers Squibb

Here are a few of the latest stories about BMY:

  • Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
  • Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
  • Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.